ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Was hoping a slight Increase today but Nothing

<< Previous

Bullboard Posts

Next >>

Comment by bball67on Jun 27, 2022 12:37pm

261 Views

Post# 34784955

RE:Was hoping a slight Increase today but Nothing

AZ, it is not a pathetic company. Iam along term holder and I will not lose half of my holdings. They have the GOOD's and it appears that no one else does. They have a computational AI model that no one else has. The Nasdaq listing is coming very soon. The naysayers are wrong, this will give us so much more attention and coverage. There is positive news coming. StayTuned

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload